Loading…
High level transient production of recombinant antibodies and antibody fusion proteins in HEK293 cells
The demand of monospecific high affinity binding reagents, particularly monoclonal antibodies, has been steadily increasing over the last years. Enhanced throughput of antibody generation has been addressed by optimizing in vitro selection using phage display which moved the major bottleneck to the...
Saved in:
Published in: | BMC biotechnology 2013-06, Vol.13 (1), p.52-52, Article 52 |
---|---|
Main Authors: | , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c623t-cfb9adfe7798f491606c244f067c58369a7b0bf96ad4030f3bbb3e962bf0e72b3 |
---|---|
cites | cdi_FETCH-LOGICAL-c623t-cfb9adfe7798f491606c244f067c58369a7b0bf96ad4030f3bbb3e962bf0e72b3 |
container_end_page | 52 |
container_issue | 1 |
container_start_page | 52 |
container_title | BMC biotechnology |
container_volume | 13 |
creator | Jäger, Volker Büssow, Konrad Wagner, Andreas Weber, Susanne Hust, Michael Frenzel, André Schirrmann, Thomas |
description | The demand of monospecific high affinity binding reagents, particularly monoclonal antibodies, has been steadily increasing over the last years. Enhanced throughput of antibody generation has been addressed by optimizing in vitro selection using phage display which moved the major bottleneck to the production and purification of recombinant antibodies in an end-user friendly format. Single chain (sc)Fv antibody fragments require additional tags for detection and are not as suitable as immunoglobulins (Ig)G in many immunoassays. In contrast, the bivalent scFv-Fc antibody format shares many properties with IgG and has a very high application compatibility.
In this study transient expression of scFv-Fc antibodies in human embryonic kidney (HEK) 293 cells was optimized. Production levels of 10-20 mg/L scFv-Fc antibody were achieved in adherent HEK293T cells. Employment of HEK293-6E suspension cells expressing a truncated variant of the Epstein Barr virus (EBV) nuclear antigen (EBNA) 1 in combination with production under serum free conditions increased the volumetric yield up to 10-fold to more than 140 mg/L scFv-Fc antibody. After vector optimization and process optimization the yield of an scFv-Fc antibody and a cytotoxic antibody-RNase fusion protein further increased 3-4-fold to more than 450 mg/L. Finally, an entirely new mammalian expression vector was constructed for single step in frame cloning of scFv genes from antibody phage display libraries. Transient expression of more than 20 different scFv-Fc antibodies resulted in volumetric yields of up to 600 mg/L and 400 mg/L in average.
Transient production of recombinant scFv-Fc antibodies in HEK293-6E in combination with optimized vectors and fed batch shake flasks cultivation is efficient and robust, and integrates well into a high-throughput recombinant antibody generation pipeline. |
doi_str_mv | 10.1186/1472-6750-13-52 |
format | article |
fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3699382</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A534630796</galeid><sourcerecordid>A534630796</sourcerecordid><originalsourceid>FETCH-LOGICAL-c623t-cfb9adfe7798f491606c244f067c58369a7b0bf96ad4030f3bbb3e962bf0e72b3</originalsourceid><addsrcrecordid>eNqNkt9rFDEQxxdRbK0--yYLvujDtvm1yeZFKKV6RwsVf72GJDu5puwlZ7Jb7H9vlrZnTwRLCJlkPvNNMjNV9RqjQ4w7foSZIA0XLWowbVrypNrfnjx9YO9VL3K-QgiLDvHn1R6hHSIdw_uVW_jVZT3ANQz1mHTIHsJYb1LsJzv6GOro6gQ2ro0PunjK9Cb2HnIx-_vtTe2mPNMlcAQfcu1DvTg9I5LWFoYhv6yeOT1keHW3HlTfP55-O1k05xeflifH543lhI6NdUbq3oEQsnNMYo64JYw5xIVtO8qlFgYZJ7nuGaLIUWMMBcmJcQgEMfSg-nCru5nMGnpbPpP0oDbJr3W6UVF7tesJ_lKt4rUq2pJ2pAi8uxNI8ecEeVRrn-cv6ABxygq3rOO03Cj-jzJM2pYw0hb07V_oVZxSKJlQmMqOMsQI_kOt9ADKBxfLE-0sqo5byjhFQvJCHf6DKqOHtbcxgPPlfCfg_U5AYUb4Na70lLM6-7x8NLv8-uXx7MWPXfbolrUp5pzAbUuCkZo7Wc29quZeLRlR7VyINw8rueXvW5f-Bnxi6nc</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1398340421</pqid></control><display><type>article</type><title>High level transient production of recombinant antibodies and antibody fusion proteins in HEK293 cells</title><source>Publicly Available Content Database</source><source>PubMed Central</source><creator>Jäger, Volker ; Büssow, Konrad ; Wagner, Andreas ; Weber, Susanne ; Hust, Michael ; Frenzel, André ; Schirrmann, Thomas</creator><creatorcontrib>Jäger, Volker ; Büssow, Konrad ; Wagner, Andreas ; Weber, Susanne ; Hust, Michael ; Frenzel, André ; Schirrmann, Thomas</creatorcontrib><description>The demand of monospecific high affinity binding reagents, particularly monoclonal antibodies, has been steadily increasing over the last years. Enhanced throughput of antibody generation has been addressed by optimizing in vitro selection using phage display which moved the major bottleneck to the production and purification of recombinant antibodies in an end-user friendly format. Single chain (sc)Fv antibody fragments require additional tags for detection and are not as suitable as immunoglobulins (Ig)G in many immunoassays. In contrast, the bivalent scFv-Fc antibody format shares many properties with IgG and has a very high application compatibility.
In this study transient expression of scFv-Fc antibodies in human embryonic kidney (HEK) 293 cells was optimized. Production levels of 10-20 mg/L scFv-Fc antibody were achieved in adherent HEK293T cells. Employment of HEK293-6E suspension cells expressing a truncated variant of the Epstein Barr virus (EBV) nuclear antigen (EBNA) 1 in combination with production under serum free conditions increased the volumetric yield up to 10-fold to more than 140 mg/L scFv-Fc antibody. After vector optimization and process optimization the yield of an scFv-Fc antibody and a cytotoxic antibody-RNase fusion protein further increased 3-4-fold to more than 450 mg/L. Finally, an entirely new mammalian expression vector was constructed for single step in frame cloning of scFv genes from antibody phage display libraries. Transient expression of more than 20 different scFv-Fc antibodies resulted in volumetric yields of up to 600 mg/L and 400 mg/L in average.
Transient production of recombinant scFv-Fc antibodies in HEK293-6E in combination with optimized vectors and fed batch shake flasks cultivation is efficient and robust, and integrates well into a high-throughput recombinant antibody generation pipeline.</description><identifier>ISSN: 1472-6750</identifier><identifier>EISSN: 1472-6750</identifier><identifier>DOI: 10.1186/1472-6750-13-52</identifier><identifier>PMID: 23802841</identifier><language>eng</language><publisher>England: BioMed Central Ltd</publisher><subject>Antigens ; Cloning ; Cloning, Molecular ; Construction contracts ; Deoxyribonucleic acid ; DNA ; Epstein-Barr virus ; Genes ; Genetic Vectors ; HEK293 Cells ; Humans ; Immunoglobulin Fc Fragments - biosynthesis ; Microbiology ; Monoclonal antibodies ; Peptide Library ; Proteins ; Recombinant Fusion Proteins - biosynthesis ; Recombinant proteins ; Ribonucleases - biosynthesis ; Single-Chain Antibodies - biosynthesis</subject><ispartof>BMC biotechnology, 2013-06, Vol.13 (1), p.52-52, Article 52</ispartof><rights>COPYRIGHT 2013 BioMed Central Ltd.</rights><rights>2013 Jäger et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</rights><rights>Copyright © 2013 Jäger et al.; licensee BioMed Central Ltd. 2013 Jäger et al.; licensee BioMed Central Ltd.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c623t-cfb9adfe7798f491606c244f067c58369a7b0bf96ad4030f3bbb3e962bf0e72b3</citedby><cites>FETCH-LOGICAL-c623t-cfb9adfe7798f491606c244f067c58369a7b0bf96ad4030f3bbb3e962bf0e72b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3699382/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/1398340421?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23802841$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Jäger, Volker</creatorcontrib><creatorcontrib>Büssow, Konrad</creatorcontrib><creatorcontrib>Wagner, Andreas</creatorcontrib><creatorcontrib>Weber, Susanne</creatorcontrib><creatorcontrib>Hust, Michael</creatorcontrib><creatorcontrib>Frenzel, André</creatorcontrib><creatorcontrib>Schirrmann, Thomas</creatorcontrib><title>High level transient production of recombinant antibodies and antibody fusion proteins in HEK293 cells</title><title>BMC biotechnology</title><addtitle>BMC Biotechnol</addtitle><description>The demand of monospecific high affinity binding reagents, particularly monoclonal antibodies, has been steadily increasing over the last years. Enhanced throughput of antibody generation has been addressed by optimizing in vitro selection using phage display which moved the major bottleneck to the production and purification of recombinant antibodies in an end-user friendly format. Single chain (sc)Fv antibody fragments require additional tags for detection and are not as suitable as immunoglobulins (Ig)G in many immunoassays. In contrast, the bivalent scFv-Fc antibody format shares many properties with IgG and has a very high application compatibility.
In this study transient expression of scFv-Fc antibodies in human embryonic kidney (HEK) 293 cells was optimized. Production levels of 10-20 mg/L scFv-Fc antibody were achieved in adherent HEK293T cells. Employment of HEK293-6E suspension cells expressing a truncated variant of the Epstein Barr virus (EBV) nuclear antigen (EBNA) 1 in combination with production under serum free conditions increased the volumetric yield up to 10-fold to more than 140 mg/L scFv-Fc antibody. After vector optimization and process optimization the yield of an scFv-Fc antibody and a cytotoxic antibody-RNase fusion protein further increased 3-4-fold to more than 450 mg/L. Finally, an entirely new mammalian expression vector was constructed for single step in frame cloning of scFv genes from antibody phage display libraries. Transient expression of more than 20 different scFv-Fc antibodies resulted in volumetric yields of up to 600 mg/L and 400 mg/L in average.
Transient production of recombinant scFv-Fc antibodies in HEK293-6E in combination with optimized vectors and fed batch shake flasks cultivation is efficient and robust, and integrates well into a high-throughput recombinant antibody generation pipeline.</description><subject>Antigens</subject><subject>Cloning</subject><subject>Cloning, Molecular</subject><subject>Construction contracts</subject><subject>Deoxyribonucleic acid</subject><subject>DNA</subject><subject>Epstein-Barr virus</subject><subject>Genes</subject><subject>Genetic Vectors</subject><subject>HEK293 Cells</subject><subject>Humans</subject><subject>Immunoglobulin Fc Fragments - biosynthesis</subject><subject>Microbiology</subject><subject>Monoclonal antibodies</subject><subject>Peptide Library</subject><subject>Proteins</subject><subject>Recombinant Fusion Proteins - biosynthesis</subject><subject>Recombinant proteins</subject><subject>Ribonucleases - biosynthesis</subject><subject>Single-Chain Antibodies - biosynthesis</subject><issn>1472-6750</issn><issn>1472-6750</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><recordid>eNqNkt9rFDEQxxdRbK0--yYLvujDtvm1yeZFKKV6RwsVf72GJDu5puwlZ7Jb7H9vlrZnTwRLCJlkPvNNMjNV9RqjQ4w7foSZIA0XLWowbVrypNrfnjx9YO9VL3K-QgiLDvHn1R6hHSIdw_uVW_jVZT3ANQz1mHTIHsJYb1LsJzv6GOro6gQ2ro0PunjK9Cb2HnIx-_vtTe2mPNMlcAQfcu1DvTg9I5LWFoYhv6yeOT1keHW3HlTfP55-O1k05xeflifH543lhI6NdUbq3oEQsnNMYo64JYw5xIVtO8qlFgYZJ7nuGaLIUWMMBcmJcQgEMfSg-nCru5nMGnpbPpP0oDbJr3W6UVF7tesJ_lKt4rUq2pJ2pAi8uxNI8ecEeVRrn-cv6ABxygq3rOO03Cj-jzJM2pYw0hb07V_oVZxSKJlQmMqOMsQI_kOt9ADKBxfLE-0sqo5byjhFQvJCHf6DKqOHtbcxgPPlfCfg_U5AYUb4Na70lLM6-7x8NLv8-uXx7MWPXfbolrUp5pzAbUuCkZo7Wc29quZeLRlR7VyINw8rueXvW5f-Bnxi6nc</recordid><startdate>20130626</startdate><enddate>20130626</enddate><creator>Jäger, Volker</creator><creator>Büssow, Konrad</creator><creator>Wagner, Andreas</creator><creator>Weber, Susanne</creator><creator>Hust, Michael</creator><creator>Frenzel, André</creator><creator>Schirrmann, Thomas</creator><general>BioMed Central Ltd</general><general>BioMed Central</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IOV</scope><scope>ISR</scope><scope>KPI</scope><scope>3V.</scope><scope>7QO</scope><scope>7TB</scope><scope>7U5</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>L7M</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20130626</creationdate><title>High level transient production of recombinant antibodies and antibody fusion proteins in HEK293 cells</title><author>Jäger, Volker ; Büssow, Konrad ; Wagner, Andreas ; Weber, Susanne ; Hust, Michael ; Frenzel, André ; Schirrmann, Thomas</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c623t-cfb9adfe7798f491606c244f067c58369a7b0bf96ad4030f3bbb3e962bf0e72b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Antigens</topic><topic>Cloning</topic><topic>Cloning, Molecular</topic><topic>Construction contracts</topic><topic>Deoxyribonucleic acid</topic><topic>DNA</topic><topic>Epstein-Barr virus</topic><topic>Genes</topic><topic>Genetic Vectors</topic><topic>HEK293 Cells</topic><topic>Humans</topic><topic>Immunoglobulin Fc Fragments - biosynthesis</topic><topic>Microbiology</topic><topic>Monoclonal antibodies</topic><topic>Peptide Library</topic><topic>Proteins</topic><topic>Recombinant Fusion Proteins - biosynthesis</topic><topic>Recombinant proteins</topic><topic>Ribonucleases - biosynthesis</topic><topic>Single-Chain Antibodies - biosynthesis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jäger, Volker</creatorcontrib><creatorcontrib>Büssow, Konrad</creatorcontrib><creatorcontrib>Wagner, Andreas</creatorcontrib><creatorcontrib>Weber, Susanne</creatorcontrib><creatorcontrib>Hust, Michael</creatorcontrib><creatorcontrib>Frenzel, André</creatorcontrib><creatorcontrib>Schirrmann, Thomas</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Opposing Viewpoints</collection><collection>Gale In Context: Science</collection><collection>Gale In Context: Global Issues</collection><collection>ProQuest Central (Corporate)</collection><collection>Biotechnology Research Abstracts</collection><collection>Mechanical & Transportation Engineering Abstracts</collection><collection>Solid State and Superconductivity Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Advanced Technologies Database with Aerospace</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>BMC biotechnology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jäger, Volker</au><au>Büssow, Konrad</au><au>Wagner, Andreas</au><au>Weber, Susanne</au><au>Hust, Michael</au><au>Frenzel, André</au><au>Schirrmann, Thomas</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>High level transient production of recombinant antibodies and antibody fusion proteins in HEK293 cells</atitle><jtitle>BMC biotechnology</jtitle><addtitle>BMC Biotechnol</addtitle><date>2013-06-26</date><risdate>2013</risdate><volume>13</volume><issue>1</issue><spage>52</spage><epage>52</epage><pages>52-52</pages><artnum>52</artnum><issn>1472-6750</issn><eissn>1472-6750</eissn><abstract>The demand of monospecific high affinity binding reagents, particularly monoclonal antibodies, has been steadily increasing over the last years. Enhanced throughput of antibody generation has been addressed by optimizing in vitro selection using phage display which moved the major bottleneck to the production and purification of recombinant antibodies in an end-user friendly format. Single chain (sc)Fv antibody fragments require additional tags for detection and are not as suitable as immunoglobulins (Ig)G in many immunoassays. In contrast, the bivalent scFv-Fc antibody format shares many properties with IgG and has a very high application compatibility.
In this study transient expression of scFv-Fc antibodies in human embryonic kidney (HEK) 293 cells was optimized. Production levels of 10-20 mg/L scFv-Fc antibody were achieved in adherent HEK293T cells. Employment of HEK293-6E suspension cells expressing a truncated variant of the Epstein Barr virus (EBV) nuclear antigen (EBNA) 1 in combination with production under serum free conditions increased the volumetric yield up to 10-fold to more than 140 mg/L scFv-Fc antibody. After vector optimization and process optimization the yield of an scFv-Fc antibody and a cytotoxic antibody-RNase fusion protein further increased 3-4-fold to more than 450 mg/L. Finally, an entirely new mammalian expression vector was constructed for single step in frame cloning of scFv genes from antibody phage display libraries. Transient expression of more than 20 different scFv-Fc antibodies resulted in volumetric yields of up to 600 mg/L and 400 mg/L in average.
Transient production of recombinant scFv-Fc antibodies in HEK293-6E in combination with optimized vectors and fed batch shake flasks cultivation is efficient and robust, and integrates well into a high-throughput recombinant antibody generation pipeline.</abstract><cop>England</cop><pub>BioMed Central Ltd</pub><pmid>23802841</pmid><doi>10.1186/1472-6750-13-52</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1472-6750 |
ispartof | BMC biotechnology, 2013-06, Vol.13 (1), p.52-52, Article 52 |
issn | 1472-6750 1472-6750 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3699382 |
source | Publicly Available Content Database; PubMed Central |
subjects | Antigens Cloning Cloning, Molecular Construction contracts Deoxyribonucleic acid DNA Epstein-Barr virus Genes Genetic Vectors HEK293 Cells Humans Immunoglobulin Fc Fragments - biosynthesis Microbiology Monoclonal antibodies Peptide Library Proteins Recombinant Fusion Proteins - biosynthesis Recombinant proteins Ribonucleases - biosynthesis Single-Chain Antibodies - biosynthesis |
title | High level transient production of recombinant antibodies and antibody fusion proteins in HEK293 cells |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-03T02%3A05%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=High%20level%20transient%20production%20of%20recombinant%20antibodies%20and%20antibody%20fusion%20proteins%20in%20HEK293%20cells&rft.jtitle=BMC%20biotechnology&rft.au=J%C3%A4ger,%20Volker&rft.date=2013-06-26&rft.volume=13&rft.issue=1&rft.spage=52&rft.epage=52&rft.pages=52-52&rft.artnum=52&rft.issn=1472-6750&rft.eissn=1472-6750&rft_id=info:doi/10.1186/1472-6750-13-52&rft_dat=%3Cgale_pubme%3EA534630796%3C/gale_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c623t-cfb9adfe7798f491606c244f067c58369a7b0bf96ad4030f3bbb3e962bf0e72b3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1398340421&rft_id=info:pmid/23802841&rft_galeid=A534630796&rfr_iscdi=true |